Why Weight Loss Can Plateau on Wegovy 2.4mg — and What Helps

What STEP 1 shows about the plateau pattern

The STEP 1 trial, published in the New England Journal of Medicine, followed adults taking semaglutide 2.4mg for 68 weeks alongside lifestyle support. Average weight loss was around 15% of body weight. What the data also show, and what tends to get less attention, is that the rate of loss was not constant. The sharpest reductions came in the early months; by week 60, many participants had reached a relative plateau even while still on the full dose.

This is not unique to semaglutide. It reflects a well-studied biological process: as body weight falls, resting energy expenditure drops, appetite-suppressing signals from fat tissue change, and the body's resistance to further loss increases. The medicine is still doing its job. The system has simply found a new set-point. A question our prescribers hear most weeks is whether a plateau means the dose has stopped working, the honest answer is that it usually means the dose has done a considerable amount of work, and now a different approach is needed to go further.

For a fuller picture of how the 2.4mg maintenance dose behaves over a full titration course, the STEP data are the reference point prescribers reach for first.

Where the 7.2mg dose fits into the picture

One development worth knowing about: in January 2026 the MHRA approved a 7.2mg maintenance dose of semaglutide (Wegovy), and on 14 April 2026 it approved a dedicated single-dose 7.2mg pen, which delivers the full maintenance amount in one injection. Trials at 7.2mg reported average weight loss of around 20.7% over 72 weeks, meaningfully more than the 2.4mg results and approaching the figures seen with tirzepatide at its higher strengths. The MHRA's approval announcement is worth reading if you want the regulatory detail.

This matters for people who have plateaued at 2.4mg because it gives a clinically assessed escalation option that previously did not exist in the UK. The decision to escalate is the prescriber's, it depends on how much weight has already been lost, tolerability so far, and whether the original comorbidity picture still applies. It is not automatic and it is not suitable for everyone. Specific dose availability is confirmed at consultation, not assumed in advance.

You can explore the full range of licensed Wegovy doses or the structure of a typical dosage plan for context on where 2.4mg sits within the schedule.

Lifestyle factors that interact with a semaglutide plateau

Dose aside, a plateau at 2.4mg is often the right moment to audit the lifestyle components running alongside treatment. GLP-1 medicines reduce appetite significantly, but they do not override physics: if intake and expenditure have both shifted to a new balance, weight stabilises. The NHS semaglutide guidance is clear that the medicine is licensed for use alongside a reduced-calorie diet and increased physical activity, not instead of them.

A few specific factors come up repeatedly in clinical practice. First, protein adequacy: on a sharply reduced appetite, it is easy to fall short of enough protein to preserve lean mass, which matters for metabolic rate. Second, strength-based activity: aerobic exercise supports cardiovascular health, but resistance training helps maintain muscle while fat is lost, and that has a direct bearing on how many calories the body uses at rest. Third, sleep: poor sleep raises ghrelin (a hunger hormone) and reduces satiety signalling; it can quietly undo a week's progress. None of these replace a prescriber's assessment, but raising them in a review conversation tends to be productive. See the Wegovy treatment overview for the broader context of what the medicine is designed to do alongside lifestyle changes.

When to ask for a clinical review

A plateau of four to six weeks is usually too short to draw firm conclusions, weight fluctuates for reasons that have nothing to do with treatment. Fluid retention, hormonal changes, and measurement timing all introduce noise. A plateau that has persisted for two to three months on 2.4mg, with no recent change in lifestyle habits, is a more meaningful signal and worth bringing to a prescriber.

The review conversation might cover: whether a dose escalation to 7.2mg is appropriate; whether the lifestyle components have drifted; whether there are new or changing health factors affecting progress; and whether continuing on the current dose still makes sense given overall results. NICE's recommendation for semaglutide under TA875 includes a review point at six months on maintenance dose, if less than 5% weight loss has been achieved by that stage, continuing is not routinely recommended. That is a formal threshold, not an informal one, and it shapes how prescribers think about ongoing treatment.

If you want to discuss where you are on treatment with a clinical team that reviews every case personally, you can speak to our prescribers through a free consultation. There is no obligation and no auto-renewal involved. Cost context, if that is part of your thinking, is covered on the Wegovy price comparison page.